Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data

Ravulizumab and eculizumab are approved terminal complement inhibitor treatments for atypical hemolytic uremic syndrome (aHUS). Ravulizumab was engineered from eculizumab to have an increased half-life allowing for reduced dosing frequency (8-weekly vs. 2-weekly). To account for differences in respe...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomazos, Ioannis, Hatswell, Anthony J., Cataland, Spero, Chen, Peter, Freemantle, Nick, Lommele, Åsa, Deighton, Kevin, Knowles, Emma, Sheerin, Neil S., Rondeau, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040196/
https://www.ncbi.nlm.nih.gov/pubmed/34931610
http://dx.doi.org/10.5414/CN110516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040196/
https://www.ncbi.nlm.nih.gov/pubmed/34931610
http://dx.doi.org/10.5414/CN110516

Ejemplares similares